Trials / Completed
CompletedNCT00744471
Tanezumab in Osteoarthritis Of The Hip
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 627 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | tanezumab | Tanezumab 10 mg IV every 8 weeks |
| BIOLOGICAL | tanezumab | Tanezumab 5mg IV every 8 weeks |
| BIOLOGICAL | tanezumab | Tanezumab 2.5 mg IV every 8 weeks. |
| BIOLOGICAL | Placebo | Placebo to match tanezumab IV every 8 weeks |
Timeline
- Start date
- 2008-11-17
- Primary completion
- 2010-03-15
- Completion
- 2010-08-13
- First posted
- 2008-09-01
- Last updated
- 2021-02-26
- Results posted
- 2021-02-26
Locations
99 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00744471. Inclusion in this directory is not an endorsement.